REGENERON PHARMACEUTICALS, INC. Cost of Revenue
REGENERON PHARMACEUTICALS, INC. (REGN) reported Cost of Revenue of $402.80 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-08.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2021-02-08
- REGENERON PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2019 was $402.80M, a 69.60% increase from fiscal 2018.
- REGENERON PHARMACEUTICALS, INC. cost of goods and services sold for fiscal 2018 was $237.50M.
| Period end | Cost of Goods and Services Sold 12 month |
|---|---|
| 2019-12-31 | $402.80M 10-K · filed 2021-02-08 |
| 2018-12-31 | $237.50M 10-K · filed 2021-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |